Nuvation Bio (NUVB) Research & Development (2020 - 2026)

Nuvation Bio (NUVB) has reported Research & Development for 7 consecutive years, with $35.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 42.46% year-over-year to $35.0 million; the TTM figure through Mar 2026 stood at $125.6 million (up 13.23% YoY), while the FY2025 annual figure was $115.1 million, up 16.13% from the prior year.
• Research & Development advanced to $35.0 million in Q1 2026 per NUVB's latest filing, from $34.3 million in the prior quarter.
• Across five years, Research & Development topped out at $35.0 million in Q1 2026 and bottomed at $12.8 million in Q1 2024.
• Historically, Research & Development has averaged $24.0 million across 5 years, with a median of $24.6 million in 2025.
• Annual changes were most pronounced in 2022 — Research & Development soared 106.09% — and 2023, when it plunged 35.72%.
• Nuvation Bio's Research & Development stood at $16.9 million in 2022, then fell by 9.01% to $15.4 million in 2023, then jumped by 90.86% to $29.3 million in 2024, then increased by 17.06% to $34.3 million in 2025, then climbed by 2.19% to $35.0 million in 2026.
• Business Quant data shows NUVB's Research & Development at $35.0 million in Q1 2026, $34.3 million in Q4 2025, and $28.8 million in Q3 2025.